INTRODUCTION CONCLUSION
• Switching moderate to severe RA patients on bDMARDs to oral tsDMARDs would reduce the cost of moderate to severe RA management in KSA • The use of oral tsDMARDs will reduce the costs associated with parenteral and subcutaneous RA drug administration (travel, accommodation, hospital visits for drug infusion and outpatient visits) for both the patients and the health systems, freeing-up healthcare resources for other medical needs • These findings provide evidence that switching to oral tsDMARDs would reduce the costs associated with the drug for both the patients and the health systems, improving quality of life for the patients and free-up available healthcare resources 
RESULTS (contd.)
• The study aimed to the assess the economic burden of moderate to severe rheumatoid arthritis (sRA) management in Kingdom of Saudi Arabia (KSA) and the cost impact of introducing tsDMARDs.
OBJECTIVE
• Currently, the high cost of RA management is due to the drug acquisition, monitoring, travel and accommodation costs for the parenterally-administered biologics. (Fig 1) • Switching from SC to oral tsDMARDs would reduce the average cost per patient by 27% (from SAR 62, 193 to SAR 45, 351) and by 45% (from SAR 82,619 to SAR 45,351) for switch from IV biologics. The average cost per patient on oral oral tsDMARDs was found to be ~60% of the average cost per patient on SC and IV biologics. (Fig 2) • Introduction of oral tsDMARDs in Saudi MOH is expected to lead to average per patient cost savings of 28%, 15% and 15% in AS1, AS2 and AS3 compared to the base case respectively. (Fig  3) . 
METHODOLOGY
• The study was done in three phases. In Phase 1, a systematic literature review was conducted to identify journal articles, reports, guidelines, conference abstracts, posters, and presentations containing relevant data on the disease background, treatment patterns and efficacy, persistence, and cold chain and storage system in KSA • Interviews with key opinion leaders were conducted in Phase 2 to understand the local RA management practices in KSA. Phase 1 and 2 provided background information and identified the data needed for the cost analysis 
Model outputs:
Average cost per patient and total cost was calculated for the base case and alternative scenario's -Base case: Based on the KOL's inputs, the current practice involved treating moderate to severe RA patients with biologics and advanced orals. Biologics were administered as SC injections (83%) and IV infusions (16%) while advanced orals were prescribed to 1% of moderate to severe RA patients -Alternative scenarios:
› Alternative Scenario 1 (AS1) assumed that all RA patients on biologics (SC and IV) would switch to oral tsDMARDs over 1 year › Alternative Scenario 2 (AS2) assumed that 30% of RA patients on IV or SC biologics would switch to oral tsDMARDs due to perceived lower efficacy. In addition, it assumed that 50% of new RA cases would be treated oral tsDMARDs . Costs were assessed over three years › Alternative Scenario 3 (AS3) assumed that 30% of RA patients on IV or SC biologics would switch to oral tsDMARDs due to perceived lower efficacy. In addition, it assumed that 100% of new RA cases would be treated with oral tsDMARDs. Costs were assessed over three years 
